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Abstract
For treatment of acne the glucuronide of retinoic acid (retinoyl β-glucuronide) is orally administered to
women of child-bearing age who are capable of conception. This therapy is safer than the oral administration
of retinoic acid because retinoic acid glucuronide is essentially non-teratogenic at dose levels effective for the
acne treatment. The retinoic acid glucuronide can be in all-trans or 13-cis form.
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[57] ABSTRACT 
For treatment of acne the glucuronide of retinoic acid 
(retinoyl B-glucuronide) is orally administered to 
women of child-bearing age who are capable of concep 
tion. This therapy is safer than the oral administration of 
retinoic acid because retinoic acid glucuronide is essen 
tially non-teratogenic at dose levels effective for the 
acne treatment. The retinoic acid glucuronide can be in 
all-trans or 13-cis form. 
4 Claims, No Drawings 
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NON-TERATOGENIC VITAMIN A PREPARATION 
FOR WOMEN OF CHILD-BEARING AGE 
GRANT REFERENCES 
Research relating to the present invention was sup 
ported in part by grants from the U.S. Government; 
namely, USDA Grant 87-CRCR-1-2320 and NIH 
Grants DK32793 and 39733. 
FIELD OF INVENTION 
The ?eld of this invention is the oral administration of 
retinoid compounds to women of child-bearing age. For 
oral treatment of acne in women who are capable of 
conception, retinoic acid (isotretinoin) has been admin 
istered with safeguards to avoiding pregnancy because 
of the known teratogenic properties of this compound. 
The present invention is concerned with the oral admin 
istration of a non-teratogenic form of retinoic acid to 
women of child-bearing age. 
BACKGROUND OF INVENTION 
Vitamin A (retinol) and most derivatives thereof 
having vitamin A activity are water-insoluble, being 
hydrophobic, lipid-soluble compounds. For example, 
retinoic acid is not water-soluble. It is known, however, 
that the glucuronide and glucose derivatives of retinoic 
acid and retinol are water-soluble. [See, for example, 
Lippel and Olson, J. Lipid. Res, 91580-586 (1968); 
Takabayashi, et al. Chem. Abs. 73:698342 (1970); Barua, 
et al., Amer. J. Clin. Nutr., 43:481-485 (1986).] Water 
soluble glycoside derivatives of vitamin A are described 
in U.S. Pat. No. 4,457,918. The retinoic acid glucuron 
ide and retinol glucuronide have been tested for effects 
in vitro on cultures of HL~6O cells (a continuous human 
myeloid cell line): Gallup, et al., First Mid-America 
Molecular Biol. Colloquium, p. 35, October 1986, and 
Proc. Soc. Exper. Biol. & Med., 186:269-274 (1987); and 
Zile, et al., Proc. Nat. Acad. Sci. USA, 84:2208-2212 
(1987). Under the conditions of the I-IL-6O systems as 
say, activity similar to retinoic acid and retinol was 
reported. Both Gallup, et al. and Zile, et al. found that 
retinoyl B-glucuronide (retinoic acid glucuronide) was 
50% less cytotoxic to HL-60 cells than all-trans retinoic 
acid. 
The all-trans form of retinoic acid has been named 
tretinoin. Cream, gel, and liquid preparations containing 
tretinoin have been approved in the United States for 
treatment of acne. These preparations are being mar 
keted under the trademark “Retin-A” by the Dermato 
logical Division of Ortho Pharmaceutical Corporation, 
Raritan, NJ. The l3-cis form of retinoic acid has been 
named isotretinoin. Its use has been approved in the 
United States for oral treatment of severe acne (e.g., 
dis?guring cystic acne). Isotretinoin is marketed under 
the trademark “Accutane” by Roche Laboratories, 
Nutley, N.J., in 10, 20 and 40 milligram (mg) capsules. 
A typical dose range is from 0.5 to 2 mg/kg body 
weight per 24 hours. At these dose levels, isotretinoin is 
highly teratogenic. 
When women of child-bearing age are being treated 
with isotretinoin for acne, extreme caution must be 
exercised to avoid the occurrence of a pregnancy dur 
ing the treatment or at least one month after the treat 
ment is discontinued. It is recommended that such 
woman patients not be treated with oral isotretinoin 
unless they agree to mandatory contraceptive measures 
and have had a negative serum pregnancy test prior to 
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beginning the therapy. Major human fetal abnormalities 
relating to “Accutane" administration have been re 
ported, and there is also an increased risk of spontane 
ous abortion. Other vitamin A congeners are also 
known to be teratogenic in animals and women. [See 
the teratogen update published by Rosa, et al., in T era 
tology, 33:355-364 (1986)]. ' 
SUMMARY OF INVENTION 
This invention is based on the discovery that retinoic 
acid glucuronide (retinoyl B-glucuronide) is essentially 
non-teratogenic at normal dose levels for oral treatment 
of acne and other conditions requiring retinoid therapy 
for women of child-bearing age. This compound may be 
in an all-trans form or in a 13-cis form. It is believed that 
the l3-cis form is preferred. Since the retinoic com 
pound of this invention is essentially non-teratogenic, 
high dose levels providing effective treatment for acne 
conditions, such as cystic acne or acne vulgaris, can be 
safely used. Where the acne is particularly resistant, it is 
believed feasible to use even higher doses than those 
which have heretofore been employed in women of 
child-bearing age without endangering the fetus if preg 
nancy should occur during treatment. It is also believed 
that other side effects which have been experienced 
with oral isotretinoin will be less evident. 
DETAILED DESCRIPTION 
Retinoic acid glucuronide (retinoyl B-glucuronide) is 
not commercially available but can be prepared by 
known synthesis procedures from commercially avail 
able starting materials. Retinoyl ?uoride is a useful 
intermediate for preparing retinoic acid glucuronide. A 
method for preparing all-trans or l3-cis retinoyl ?uo 
ride is described in Barua and Olson, Biochimica. et 
Biophysica Acta, 757:288-299 (1983); and U.S. Pat. No. 
4,473,503. A two-step process for preparing retinoic 
acid glucuronide from retinoyl ?uoride is described in > 
Barua and Olson, J. Lipid. Res., 26:1277-1282 (1985). 
Retinoyl fluoride is first reacted with 6,3-glucuronolac 
tone to produce 6,3-lactone of retinoyl glucuronic acid, 
which is then hydrolyzed with dilute alkali to give the 
retinoyl B-glucuronide. A one-step process for this syn 
thesis is described in U.S. patent application Ser. No. 
941,637, ?led Dec. 15, 1986. The reaction is carried out 
in an acetone-water mixture proportioned so that both 
the water-insoluble retinoyl ?uoride and the water-solu 
ble glucuronic acid are maintained in solution. 
This invention is concerned with the treatment of 
women of child-bearing age for acne or other condition 
requiring oral retinoid therapy. Although the women 
are capable of conception, the compound of this inven 
tion can be administered in effective amounts without 
the danger of teratogenicity if the woman patient be 
comes pregnant during the therapy or shortly thereaf 
ter. It is believed that if necessary retinoic acid glucu 
ronide can even be orally administered to pregnant 
women without teratogenic consequences. 
Oral doses of retinoic acid glucuronide can range 
from 0.25 to 4 milligrams (mg) per kilogram of the 
patient’sbody weight per 24 hours. This refers to total 
doses, which may be divided into two or more individ 
ual doses within each 24 hour period. For most pur 
poses, such as the treatment of cystic acne, it is believed 
that the preferred dose range will be from about 0.5 to 
2 mg/kg body weight/24 hrs. The retinoic acid glucu 
ronide should be prepared in premeasured oral dose 
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units. For example, the dose units may comprise tablets 
or capsules, and each tablet or each capsule should 
contain an amount of the compound for convenient 
administration, such as 10, 20, or 40 mg. Incorporation 
of the compound in the form of a dry powder in gelatin 
capsules provides a convenient dose unit. Alternatively, 
the compound in the form of a dry powder may be 
tabletted, and for this purpose may be combined with a 
tabletting sugar or other diluent such as lactose. 
The method of this invention is further illustrated by 
the following examples. 
EXAMPLE I _ 
Synthesis of Retinoyl B-Glucuronide 
Retinoic Acid Glucuronide 
Retinoyl fluoride (2.4 g, 7.9 mmol) was dissolved in 
200 ml of acetone. D-glucuronic acid (6 g, 31 mmol) 
dissolved in 50 ml of water and sodium bicarbonate (970 
mg) dissolved in 50 ml of water were added to the 
retinoyl ?uoride solution. The mixture was stirred at 
room temperature for 20-24 hrs. The solution was neu 
tralized with 1N HCl, diluted with water, and the prod 
uct was extracted with ethyl acetate. The extract was 
washed with water, dried over anhydrous sodium sul 
fate and then evaporated to dryness in a rotary evapora 
tor. The residue was dissolved in 2-3 ml of diethyl ether 
and transferred to a silica gel (for dry column chroma 
tography, wet packed with hexane) column. The col 
umn was developed with hexane containing diethyl 
ether (5»50%) to remove retinoic acid and other prod 
ucts. The major yellow band containing retinoyl glucu 
ronide was next eluted with a mixture of 
CH2Cl2/CH3OH (1:1). The solvent was evaporated to 
dryness to give solid retinoyl [ii-glucuronide (2.3 g, 
60%). This preparation consisted mainly of the all-trans 
isomer, and can be used as such. 
An analytically pure sample of retinoyl B-glucuro 
nide was obtained by HPLC of the above preparation 
on a Whatman ODS-3 column (M9, 50 'cm) using me 
thanol/water (7:3) containing 10 mM ammonium ace 
tate at a flow rate of 3 ml/min. Retinoyl B-glucuronide 
(t R=49.7 min) separated from traces of isomers or 
anomers (tR=46.4 min). The eluate carrying retinoyl 
,B-glucuronide was diluted with water and made just 
acidic with 0.1N HCl. The product was extracted with 
ethyl acetate. The extract was washed with water, dried 
over anhydrous sodium sulfate, and then evaporated to 
dryness. The residue was dissolved in a small volume of 
diethyl ether and all-trans retinoyl B-glucuronide was 
precipitated with hexane. The solid was separated and 
dried. All-trans retinoyl ,B-glucuronidezmp. 142°—143° 
C. (darkens at 125° C.); UVMX36O nm (E1c,,,=1O65) in 
methanol and 365 nm in water. The lH-NMR, IR and 
Mass spectra and C, H analysis results were consistent 
with the structure. The compound is soluble in water. 
Incubation of retinoyl B-glucuronidase (from E. 0011) in 
phosphate buffer (pH 6.8) for 0.5-2 hrs generated reti 
noic acid. 
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EXAMPLE II 
All-trans retinoic acid glucuronide was tested for 
teratogenicity in pregnant rats. 
Experimental Plan 
The retinoic acid glucuronide dissolved in vegetable 
oil. Equivalent amount of all-trans retinoic acid was also 
dissolved in the vegetable oil. Groups of pregnant rats 
were dosed orally with either retinoid glucuronide or 
retinoic acid on day 8.5 of gestation. This particular day 
was chosen because other workers have demonstrated 
that maximal fetal damage results when teratogens are 
administered on day 8-10 of gestation in the rat. The 
rats were killed on day 19.5 of a 21 day gestational 
period, and the fetuses were examined for viability, 
growth, and developmental abnormalities. 
Experimental Procedure 
Rats that became pregnant during the same night 
were selected for the study. The rats were divided into 
3 groups. Rats in Group 1 received orally 55 mg of the 
all-trans retinoic acid glucuronide (equivalent to 35 mg 
of retinoic acid) or a very large dose of 108 mg of the 
glucuronide in peanut oil. Rats in Group 2 received 
orally 35 mg of all-trans retinoic acid in peanut oil. Rats 
in Group 3 received no retinoid and served as control. 
The rats were then allowed to grow normally and on 
day 19, they were killed and fetuses were examined. 
Results 
It was observed that the rats given large doses of the 
retinoid glucuronide did not show any sign of teratoge 
nicity. All the pups were normal and live. On the other 
hand, the rats given the same large doses of retinoic acid 
did not carry the pregnancy to term--a1l the embryos 
died and were being resorbed. Results are summarized 
in Table A. 
TABLE A 
Dose/ Live 
Dams Compound Rat Birth Resorbedul 
(No) Tested (mg) (‘70) (‘72) 
3 Retinoyl 55 100 0.03 
glucuronide 
l Retinoyl 108 100 0 
glucuronide 
3 Retinoic acid 35 O 100 
5 None (control) 0 100 0.04 
(“At implantation of fetus. 
We claim: 
1. A method of treating acne in a woman patient of 
child-bearing age who is capable of conception, com 
prising orally administering to said patient retinoic acid 
glucuronide, said glucuronide being in an all-trans or 
13-cis form and being administered in an effective 
amount for said acne treatment. 
2. The method of treating acne of claim 1 in which 
said glucuronide is in an all-trans form. 
3. The method of treating acne of claim 1 in which 
said glucuronide is in a l3-cis form. 
4. The method of treating acne of claims 1, 2 or 3 in 
which the amount of said glucuronide administered to 
said patient is from about 0.5 to 2 milligrams per kilo 
gram of patient body weight per 24 hours. 
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